TITLE:
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

CONDITION:
HIV Infections

INTERVENTION:
Lamivudine

SUMMARY:

      To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in
      combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination
      with AZT.

      PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label
      combination therapy.
    

DETAILED DESCRIPTION:

      Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC
      plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52
      weeks.

      PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an
      open-label basis. Open-label therapy continues with follow-up every 8 weeks until
      intolerable toxicity occurs or study terminates.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV positivity.

          -  CD4 count 100-300 cells/mm3.

          -  Prior AZT therapy for 24 or more weeks and currently on AZT.

        Exclusion Criteria

        Patients with the following prior conditions are excluded:

          -  History of intolerance to AZT.

          -  History of grade 2 or worse peripheral neuropathy.

        Prior Medication:

        Excluded:

          -  Any prior antiretroviral therapy other than AZT.

        Required:

          -  Concomitant AZT therapy.

        Required:

          -  At least 24 weeks of prior AZT.
      
